Perjeta (pertuzumab)

pCPA File Number: 23431

Negotiation Status:

Active Negotiation

Indication(s):

In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PX0379-000

pCPA Engagement Letter Issued:

2026-02-11

Negotiation Process Concluded:

Not Applicable